//=time() ?>
Our first issue of 2022 is live! 🎉
Featuring trials in #sicklecell & #GVHD, a study on #QoL in #mpnsm, a review on drug-drug interactions between #hemonc targeted therapies & antifungals, #VITT and more! https://t.co/ncz5PtUKup
Our November issue is here! Featuring our joint Series with @LancetLongevity on #hemonc in older people (https://t.co/LqBcyGyQAY), trials in myeloma & lymphoma, a study redefining low risk high hyperdiploidy in ped ALL, & much more #mmsm #lymsm #leusm
➡️https://t.co/EyrqUdHpyd
commission done for @Raikonos
and their partner Duke, this character lovingly referred to as a Thembo Hemonculous
Venetoclax-based regimens for NPM1-mutated #AML
Read about it here👉https://t.co/7jgUWTy2sQ👈
#LEUsm #HemOnc #AMLsm #oncoalert @VJHemOnc